Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Wang F, et al. Among authors: hu xc. Ann Oncol. 2019 Sep 1;30(9):1479-1486. doi: 10.1093/annonc/mdz197. Ann Oncol. 2019. PMID: 31236579 Free PMC article. Clinical Trial.
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, Wang X, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Shen K, Yu S, Li H, Tang L, Qiu R; study group of BG01-1323L. Xu B, et al. Among authors: hu xc. Ann Oncol. 2021 Feb;32(2):218-228. doi: 10.1016/j.annonc.2020.10.600. Epub 2020 Nov 11. Ann Oncol. 2021. PMID: 33188874 Free article. Clinical Trial.
[Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].
Zhang L, Gong JF, Pan HM, Bai YX, Liu TS, Cheng Y, Chen YC, Huang JY, Xu TT, Ge FJ, Hsu WL, Shi J, Hu XC, Shen L. Zhang L, et al. Among authors: hu xc. Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Oct 18;54(5):971-980. doi: 10.19723/j.issn.1671-167X.2022.05.026. Beijing Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 36241241 Free PMC article. Clinical Trial. Chinese.
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial.
Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, Zeng L, Zhang M. Jiang ZF, et al. Among authors: hu xc. Ann Oncol. 2013 Nov;24(11):2766-72. doi: 10.1093/annonc/mdt246. Epub 2013 Jul 14. Ann Oncol. 2013. PMID: 23857960 Free article. Clinical Trial.
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC. Zhang J, et al. Among authors: hu xc. Ann Oncol. 2018 Aug 1;29(8):1741-1747. doi: 10.1093/annonc/mdy209. Ann Oncol. 2018. PMID: 29905759 Free article. Clinical Trial.
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S; NO16853 trial group. Buzdar AU, et al. Ann Oncol. 2012 Mar;23(3):589-597. doi: 10.1093/annonc/mdr256. Epub 2011 Jun 1. Ann Oncol. 2012. PMID: 21633047 Free article. Clinical Trial.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. Cardoso F, et al. Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979513 Free PMC article. No abstract available.
[Study of bioequiavailability of paclitaxel for Injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer].
Bian L, Geng CZ, Ouyang QC, Hu XC, Peng YY, Xiao JY, Wang MX, Yang N, Yuan J, Wang YM, Jiang ZF. Bian L, et al. Among authors: hu xc. Zhonghua Yi Xue Za Zhi. 2018 Apr 24;98(16):1236-1241. doi: 10.3760/cma.j.issn.0376-2491.2018.16.010. Zhonghua Yi Xue Za Zhi. 2018. PMID: 29747311 Clinical Trial. Chinese.
280 results